Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026

Same author

Decreased Myocardial 123I-MIBG Uptake Without Sympathetic Denervation: An Autopsy Report of Autoimmune Autonomic Ganglionopathy.

Brain and behavior·2026

Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026

Same author

Another Microlesion Effect after STN-DBS for Parkinson's Disease.

Movement disorders clinical practice·2025

Same author

Levodopa-carbidopa intestinal gel for multiple system atrophy with motor fluctuations: a case series.

Therapeutic advances in neurological disorders·2025

Same author

The Utility of Long-Read Sequencing in Diagnosing Early Onset Parkinson's Disease.

Annals of neurology·2024

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

[Relationship between alpha-synuclein and Parkinson's disease].

Kenya Nishioka¹, Nobutaka Hattori

¹Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Brain and Nerve = Shinkei Kenkyu No Shinpo

|August 24, 2007

Summary

Alpha-synuclein (SNCA) gene multiplications cause severe Parkinson's disease, with triplications leading to worse outcomes than duplications. This review covers SNCA's clinical and genetic roles in neurodegeneration.

More Related Videos

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Related Experiment Videos

Last Updated: Jul 12, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Area of Science:

Neuroscience
Genetics

Context:

Alpha-synuclein (SNCA) is a key component of Lewy bodies, found in neurodegenerative conditions like Parkinson's and Alzheimer's diseases.
SNCA multiplications have been identified in autosomal familial Parkinson's disease (ADPD), impacting protein expression levels.

Purpose:

To review the clinical and genetic aspects of alpha-synuclein (SNCA), including multiplications and missense mutations.
To explore the correlation between SNCA gene dosage (duplication vs. triplication) and disease severity in Parkinson's disease.

Summary:

SNCA multiplications, particularly triplications, are linked to severe Parkinson's disease with cognitive decline and parkinsonism, often presenting with young onset and levodopa non-responsiveness.
Duplications show a milder disease course, similar to sporadic cases, suggesting a gain-of-function mechanism for SNCA in neurodegeneration.
Differences in SNCA gene length (triplication vs. duplication) influence clinical presentation and prognosis.

Impact:

Understanding SNCA's role in Parkinson's disease pathogenesis, especially the impact of gene copy number variations.
Provides insights into genotype-phenotype correlations for familial Parkinson's disease.
Highlights potential therapeutic targets related to alpha-synuclein levels and function.